World Pharma News Digest - 07.12.2009
0 views
Skip to first unread message
Ruslan David
Dec 7, 2009, 3:29:46 AM12/7/09
to worldph...@googlegroups.com
Sanofi-aventis enters into an Exclusive Global Licensing Agreement with The Rockefeller University
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced an exclusive global licensing agreement with The Rockefeller University (New York, NY) concerning a novel monoclonal antibody, targeting certain specific forms of the Amyloid Beta parenchymal plaque for the treatment of Alzheimer's disease.
Read more...
http://www.worldpharmanews.com/content/view/1049/1/
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced an exclusive global licensing agreement with The Rockefeller University (New York, NY) concerning a novel monoclonal antibody, targeting certain specific forms of the Amyloid Beta parenchymal plaque for the treatment of Alzheimer's disease.
Read more...
http://www.worldpharmanews.com/content/view/1049/1/
New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists
Each year, hundreds of undergraduate students from across the United States (U.S.) and Europe participate in the Amgen Scholars Program to gain hands-on laboratory experience under renowned faculty members at the world's leading universities. Now, the Amgen Scholars - past, present and future - will have exclusive access to the online Amgen Scholars Community.
Read more...
http://www.worldpharmanews.com/content/view/1048/1/
Each year, hundreds of undergraduate students from across the United States (U.S.) and Europe participate in the Amgen Scholars Program to gain hands-on laboratory experience under renowned faculty members at the world's leading universities. Now, the Amgen Scholars - past, present and future - will have exclusive access to the online Amgen Scholars Community.
Read more...
http://www.worldpharmanews.com/content/view/1048/1/
AstraZeneca and Targacept Form Global Collaboration and Licence Agreement
AstraZeneca and Targacept, Inc. announced a collaboration and licence agreement for the global development and commercialisation of TC-5214, Targacept's late-stage investigational product for major depressive disorder (MDD). TC-5214, which recently completed a phase IIb clinical trial, is a nicotinic channel blocker that is thought to treat depression by modulating the activity of various neuronal nicotinic receptor (NNR) subtypes.
Read more...
http://www.worldpharmanews.com/content/view/1047/1/
AstraZeneca and Targacept, Inc. announced a collaboration and licence agreement for the global development and commercialisation of TC-5214, Targacept's late-stage investigational product for major depressive disorder (MDD). TC-5214, which recently completed a phase IIb clinical trial, is a nicotinic channel blocker that is thought to treat depression by modulating the activity of various neuronal nicotinic receptor (NNR) subtypes.
Read more...
http://www.worldpharmanews.com/content/view/1047/1/
Resource Guide About Key Issues Facing the Pharmaceutical Industry
The educational resource, "The Value of Medicine, Improving Health... Improving Life," created by Lilly USA (NYSE: LLY), is now available for download. The booklet supports Lilly's commitment to providing "Answers That Matter" and encourages an open dialogue with patients, providers, payers and the public about pharmaceutical industry practices.
Read more...
http://www.worldpharmanews.com/content/view/1046/1/
The educational resource, "The Value of Medicine, Improving Health... Improving Life," created by Lilly USA (NYSE: LLY), is now available for download. The booklet supports Lilly's commitment to providing "Answers That Matter" and encourages an open dialogue with patients, providers, payers and the public about pharmaceutical industry practices.
Read more...
http://www.worldpharmanews.com/content/view/1046/1/
GSK's Arepanrix™ H1N1 pandemic vaccine prequalified by the World Health Organization
GlaxoSmithKline (GSK) announced that the World Health Organization (WHO) has awarded prequalification for global use of Arepanrix™, GSK's adjuvanted H1N1 pandemic vaccine manufactured in Canada. This is the first prequalification for an H1N1 pandemic vaccine, and is a key step in ensuring the vaccine can be distributed to developing countries.
Read more...
http://www.worldpharmanews.com/content/view/1045/1/
GlaxoSmithKline (GSK) announced that the World Health Organization (WHO) has awarded prequalification for global use of Arepanrix™, GSK's adjuvanted H1N1 pandemic vaccine manufactured in Canada. This is the first prequalification for an H1N1 pandemic vaccine, and is a key step in ensuring the vaccine can be distributed to developing countries.
Read more...
http://www.worldpharmanews.com/content/view/1045/1/
Merck KGaA Receives Refuse to File Letter from FDA on Cladribine Tablets New Drug Application
Merck KGaA announced that its US affiliate received a refuse to file letter from the US Food and Drug Administration (FDA) on the New Drug Application (NDA) for Cladribine Tablets, Merck Serono's proprietary investigational oral formulation of cladribine, as a therapy for relapsing forms of multiple sclerosis (MS).
Read more...
http://www.worldpharmanews.com/content/view/1044/1/
Merck KGaA announced that its US affiliate received a refuse to file letter from the US Food and Drug Administration (FDA) on the New Drug Application (NDA) for Cladribine Tablets, Merck Serono's proprietary investigational oral formulation of cladribine, as a therapy for relapsing forms of multiple sclerosis (MS).
Read more...
http://www.worldpharmanews.com/content/view/1044/1/
Pfizer And Protalix Enter Into Agreement To Develop And Commercialize Gaucher's Disease Treatment
Pfizer (NYSE: PFE) and Protalix (NYSE-Amex: PLX) have entered into an agreement to develop and commercialize taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) in development for the potential treatment of Gaucher's disease.
Read more...
http://www.worldpharmanews.com/content/view/1043/1/
Pfizer (NYSE: PFE) and Protalix (NYSE-Amex: PLX) have entered into an agreement to develop and commercialize taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) in development for the potential treatment of Gaucher's disease.
Read more...
http://www.worldpharmanews.com/content/view/1043/1/
Message on the occasion of World AIDS Day
On this World AIDS Day we are filled with both hope and concern.
Hope because significant progress has been made towards universal access. New HIV infections have dropped. Fewer children are born with HIV. And more than 4 million people are on treatment.
Read more...
http://www.worldpharmanews.com/content/view/1042/1/
On this World AIDS Day we are filled with both hope and concern.
Hope because significant progress has been made towards universal access. New HIV infections have dropped. Fewer children are born with HIV. And more than 4 million people are on treatment.
Read more...
http://www.worldpharmanews.com/content/view/1042/1/
"Positive Charge" to Help Address Barriers and Provide Support to People Living with HIV/AIDS
The National AIDS Fund (NAF) and Bristol-Myers Squibb Company (NYSE: BMY) announced their intention to launch "Positive Charge", a new multiyear initiative aimed at helping to break down the barriers that prevent people living with HIV from receiving HIV care, treatment and necessary support. The initiative is slated to launch in January 2010.
Read more...
http://www.worldpharmanews.com/content/view/1041/1/
The National AIDS Fund (NAF) and Bristol-Myers Squibb Company (NYSE: BMY) announced their intention to launch "Positive Charge", a new multiyear initiative aimed at helping to break down the barriers that prevent people living with HIV from receiving HIV care, treatment and necessary support. The initiative is slated to launch in January 2010.
Read more...
http://www.worldpharmanews.com/content/view/1041/1/
Bayer Starts Phase III Trial with Florbetaben
Bayer Schering Pharma AG, Germany, is progressing with the development of florbetaben to support Alzheimer diagnosis. On the occasion of the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), the company announced the enrollment of first patients in an international clinical Phase III trial to evaluate the efficacy and safety of florbetaben (BAY 94-9172) PET imaging in the detection of beta-Amyloid deposition in the brain.
Read more...
http://www.worldpharmanews.com/content/view/1040/1/
Bayer Schering Pharma AG, Germany, is progressing with the development of florbetaben to support Alzheimer diagnosis. On the occasion of the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), the company announced the enrollment of first patients in an international clinical Phase III trial to evaluate the efficacy and safety of florbetaben (BAY 94-9172) PET imaging in the detection of beta-Amyloid deposition in the brain.
Read more...
http://www.worldpharmanews.com/content/view/1040/1/
PharmaNews.eu / Latest News
European Medicines Agency advises of risk of fever in young children following vaccination with Pandemrix
http://www.pharmanews.eu/emea/402-european-medicines-agency-advises-of-risk-of-fever-in-young-children-following-vaccination-with-pandemrix
http://www.pharmanews.eu/emea/402-european-medicines-agency-advises-of-risk-of-fever-in-young-children-following-vaccination-with-pandemrix
Bayer Team wins the "Deutscher Zukunftspreis" awarded by the German President
http://www.pharmanews.eu/bayer/401-bayer-team-wins-the-qdeutscher-zukunftspreisq-awarded-by-the-german-president
http://www.pharmanews.eu/bayer/401-bayer-team-wins-the-qdeutscher-zukunftspreisq-awarded-by-the-german-president
Multaq® Approved in the European Union for patients with atrial fibrillation
http://www.pharmanews.eu/sanofi-aventis/400-multaqr-approved-in-the-european-union-for-patients-with-atrial-fibrillation
http://www.pharmanews.eu/sanofi-aventis/400-multaqr-approved-in-the-european-union-for-patients-with-atrial-fibrillation
Bayer Schering Pharma to collaborate with Micromet on novel approach to cancer therapy
http://www.pharmanews.eu/bayer/399-bayer-schering-pharma-to-collaborate-with-micromet-on-novel-approach-to-cancer-therapy
http://www.pharmanews.eu/bayer/399-bayer-schering-pharma-to-collaborate-with-micromet-on-novel-approach-to-cancer-therapy
European Commission tops a billion Euros invested in the fight against the global AIDS epidemic
http://www.pharmanews.eu/european-commission/398-european-commission-tops-a-billion-euros-invested-in-the-fight-against-the-global-aids-epidemic
http://www.pharmanews.eu/european-commission/398-european-commission-tops-a-billion-euros-invested-in-the-fight-against-the-global-aids-epidemic
Message on the occasion of World AIDS Day
http://www.pharmanews.eu/research-and-development/397-message-on-the-occasion-of-world-aids-day
http://www.pharmanews.eu/research-and-development/397-message-on-the-occasion-of-world-aids-day
Major European regulatory milestone in cardiovascular protection for Micardis® (telmisartan)
http://www.pharmanews.eu/boehringer-ingelheim/396-major-european-regulatory-milestone-in-cardiovascular-protection-for-micardisr-telmisartan
http://www.pharmanews.eu/boehringer-ingelheim/396-major-european-regulatory-milestone-in-cardiovascular-protection-for-micardisr-telmisartan
High salt intake means more strokes and heart disease
http://www.pharmanews.eu/research-and-development/395-high-salt-intake-means-more-strokes-and-heart-disease
http://www.pharmanews.eu/research-and-development/395-high-salt-intake-means-more-strokes-and-heart-disease
Innovations in Oncology Drug Discovery, Development & Delivery
http://www.pharmanews.eu/conferences-and-events/394-innovations-in-oncology-drug-discovery-development-a-delivery
http://www.pharmanews.eu/conferences-and-events/394-innovations-in-oncology-drug-discovery-development-a-delivery
ExL Pharma's European Digital Marketing and Public Relations Conferences
http://www.pharmanews.eu/conferences-and-events/393-exl-pharmas-european-digital-marketing-and-public-relations-conferences
http://www.pharmanews.eu/conferences-and-events/393-exl-pharmas-european-digital-marketing-and-public-relations-conferences
With best regards,
Ruslan David, MD
Administrator/Editor
Ruslan David, MD
Administrator/Editor
PS:
Subscribe to World Pharma News alerts by Email (a free service delivered by Google) -
http://feedburner.google.com/fb/a/mailverify?uri=worldpharmanews&loc=en_US
Subscribe to World Pharma News alerts by Email (a free service delivered by Google) -
http://feedburner.google.com/fb/a/mailverify?uri=worldpharmanews&loc=en_US
Subscribe to PharmaNews.eu alerts by Email (a free service delivered by Google) -
http://feedburner.google.com/fb/a/mailverify?uri=pharmanewseu&loc=en_US
http://feedburner.google.com/fb/a/mailverify?uri=pharmanewseu&loc=en_US
Reply all
Reply to author
Forward
0 new messages